Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has been given an average recommendation of “Buy” by the six research firms that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $23.67.
A number of analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Acrivon Therapeutics in a research report on Thursday, November 14th. BMO Capital Markets lowered their price target on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. LADENBURG THALM/SH SH raised shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Monday, September 16th. Piper Sandler Companies reissued a “buy” rating and issued a $30.00 target price on shares of Acrivon Therapeutics in a research note on Friday, September 6th. Finally, JMP Securities restated a “market outperform” rating and set a $17.00 price target on shares of Acrivon Therapeutics in a research note on Monday, September 16th.
View Our Latest Stock Analysis on ACRV
Acrivon Therapeutics Stock Up 0.8 %
Hedge Funds Weigh In On Acrivon Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC increased its holdings in shares of Acrivon Therapeutics by 78.2% during the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock worth $31,093,000 after buying an additional 2,353,000 shares in the last quarter. Sands Capital Ventures LLC grew its position in Acrivon Therapeutics by 28.4% during the 2nd quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company’s stock worth $12,311,000 after acquiring an additional 470,000 shares during the last quarter. American International Group Inc. increased its holdings in Acrivon Therapeutics by 39.2% during the 1st quarter. American International Group Inc. now owns 6,016 shares of the company’s stock valued at $43,000 after purchasing an additional 1,695 shares in the last quarter. Marshall Wace LLP raised its position in Acrivon Therapeutics by 58.8% in the 2nd quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock valued at $5,503,000 after purchasing an additional 351,397 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Acrivon Therapeutics by 6.6% in the first quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock worth $3,626,000 after purchasing an additional 31,208 shares in the last quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.
About Acrivon Therapeutics
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Stories
- Five stocks we like better than Acrivon Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- Election Stocks: How Elections Affect the Stock Market
- MarketBeat Week in Review – 11/25 – 11/29
- How to Find Undervalued Stocks
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.